Project
A multicentre randomised phase III trial comparing atezolizumab
Ongoing - recruitment active · 2019 until 2025
Früh Martin
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2019
End Date
2025
Financing
Others
Study Design
Phase III
Keywords
Mesotheliom, Atezolizumab, Chemotherapie, Erstlinientherapie
Homepage
Partner
ETOP/SAKK
Brief description/objective
Evaluation einer Immuntherapie in der ersten Therapielinie
in Kombination mit einer Standard Chemo-/Avastintherapie
bei Patienten mit malignem Mesotheliom